This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zoetis Inc. came into existence following Pfizer’s decision to spin off its animal health business. he company is a leader in the discovery, development, manufacture and commercialization of animal health medicines, vaccines and diagnostic products with a focus on both livestock and companion animals. Zoetis has a diversified business, which caters to eight core species — cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals).
Can Zoetis (ZTS) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DEF
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: Texas Instruments, Charter, Lowe's, Caterpillar and Zoetis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Texas Instruments, Charter, Lowe's, Caterpillar and Zoetis
Top Analyst Reports for Texas Instruments, Charter & Lowe's
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Texas Instruments (TXN), Charter Communications (CHTR) and Lowe's (LOW).
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Zoetis Surges 45.3% YTD on Strong Portfolio & New Approvals
by Zacks Equity Research
Zoetis (ZTS) surges on strong performance year to date, backed by a solid portfolio and prudent acquisitions.
Top Analyst Reports for Alibaba, Disney & Morgan Stanley
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group (BABA), Disney (DIS) and Morgan Stanley (MS).
Zacks.com featured highlights include: ResMed, Microsoft, Zoetis and Ruth???s Hospitality
by Zacks Equity Research
Zacks.com featured highlights include: ResMed, Microsoft, Zoetis and Ruth???s Hospitality
Zoetis (ZTS) Up 0.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks.com featured highlights include: ResMed, Microsoft, Zoetis and Ruth's Hospitality
by Zacks Equity Research
Zacks.com featured highlights include: ResMed, Microsoft, Zoetis and Ruth's Hospitality
4 GARP Stocks to Scoop Up for Maximum Returns
by Zacks Equity Research
If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.
JAZZ vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Zoetis (ZTS) Acquires ZNLabs to Bolster Diagnostics Portfolio
by Zacks Equity Research
Zoetis (ZTS) acquires ZNLabs and expands its reference laboratory capabilities in the United States.
Is Zoetis (ZTS) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ZTS) Outperforming Other Medical Stocks This Year?
Zacks.com featured highlights include: Heico, Microsoft, Zoetis and Cadence Design System
by Zacks Equity Research
Zacks.com featured highlights include: Heico, Microsoft, Zoetis and Cadence Design System
4 GARP Stocks for a Winning Portfolio
by Zacks Equity Research
Growth at a reasonable price or GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for FTCS
JAZZ or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Zoetis (ZTS) Beats on Earnings in Q3, Reports In-Line Sales
by Zacks Equity Research
Zoetis (ZTS) beats earnings estimates, while sales are in line in the third quarter of 2019.
Zoetis (ZTS) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of 5.62% and 0.17%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Zoetis (ZTS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis (ZTS) is expected to provide pipeline updates during the third-quarter earnings call.
Zacks.com featured highlights include: Heico, Microsoft, Zoetis and Cadence
by Zacks Equity Research
Zacks.com featured highlights include: Heico, Microsoft, Zoetis and Cadence
Zoetis (ZTS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Zoetis (ZTS) closed at $127.92, marking a +0.25% move from the previous day.
Zoetis (ZTS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.